Vietnam to Build Vaccine Plant Worth Over VND2.5 Trillion, Aiming for 2028 Production
Vietnam's VNVC is constructing a vaccine and biological product plant worth over VND2.5 trillion (approximately $100 million USD) in partnership with French pharmaceutical giant Sanofi. Operations are slated to begin by late 2027, with the first production of next-generation vaccines expected in 2028, bolstering Vietnam's self-sufficiency and technological capabilities in pharmaceuticals.
This article requires PRO
This article is outside the free access window or is a special report. PRO unlocks it and the full archive.
Related articles
- Vietnam Strengthens Vaccine Manufacturing Localization with France to Enhance Health Security and Economic Growth
Vietnam and France are strengthening their collaboration on vaccine manufacturing localization, a strategic move to establish health security and achieve economic growth targets. French pharmaceutical giant Sanofi and Vietnam's VNVC are partnering on technology transfer and human resource development.
- Vietnam Fosters Vaccine Manufacturing Localization
Vietnam is promoting technology transfer and human resource development to strengthen domestic vaccine manufacturing capabilities. This is part of a national strategy aimed at healthcare self-sufficiency, improved public healthcare, and international contributions.